PRME
What one share of Prime Medicine holds
Biological Products, (No Diagnostic Substances)
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.
Prime Medicine’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.09 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.91 |
| Cash and investments | $0.26 |
| Book value | $0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $1.97 | −$1.92 | $0.24 | −$2.34 | — | $0.89 |
| 2021 | $0.00 | −$14.19 | $0.32 | −$2.95 | — | — |
| 2022 | $0.00 | −$4.19 | $0.47 | −$4.36 | — | — |
| 2023 | $0.00 | −$2.18 | $0.10 | −$1.91 | — | $1.37 |
| 2024 | $0.03 | −$1.65 | $0.06 | −$1.10 | — | $1.17 |
| 2025 | $0.03 | −$1.35 | $0.03 | −$1.12 | — | $0.67 |